title: Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study.
abstract: OBJECTIVE
  Despite the increased prevalences of hypertension, type 2 diabetes mellitus (T2DM), hyperlipidemy, and obesity in patients with non-functioning adrenal adenomas (NFAAs), there is a paucity of data on long-term atherosclerotic morbidity as well as the long-term cardiovascular effects of adrenalectomy in these patients.
  
  
  METHODS
  This retrospective study includes the results of baseline and follow-up investigations of 125 patients (29 males and 96 females; mean age 60.1 years) with NFAAs referred for endocrine evaluation between 1990 and 2001. Of the 125 patients, 47 underwent unilateral adrenalectomy, while 78 patients were followed conservatively. These patients were reinvestigated after a mean follow-up time of 9.1 (5-16) years in 2006, with special emphasis on laboratory and other atherosclerotic risk factors (ARF), vascular events, and interventions.
  
  
  RESULTS
  The prevalences of hypertension, impaired glucose tolerance or T2DM, hyperlipidemy, and obesity were 82, 43, 58, and 50%, and 89, 58, 82, and 50% at baseline and follow-up, respectively. None of the investigated ARF prevalences were different between patients treated and not treated with adrenalectomy, and between patients with and without subclinical Cushing's syndrome. The prevalences of angina pectoris, acute myocardial infarction, coronary, and peripheral arterial interventions or cerebrovascular stroke did not differ significantly between patients treated and not treated with adrenalectomy.
  
  
  CONCLUSIONS
  Our study confirms previous investigations reporting markedly increased prevalences of various ARF in patients with NFAAs. Adrenalectomy performed in these patients failed to decrease the prevalence of ARF and atherosclerotic morbidity.
authors.affiliation: 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: Márta
authors.initials: M
authors.lastname: Sereg
authors.forename: Agnes
authors.initials: A
authors.lastname: Szappanos
authors.forename: Judit
authors.initials: J
authors.lastname: Toke
authors.forename: Kinga
authors.initials: K
authors.lastname: Karlinger
authors.forename: Karolina
authors.initials: K
authors.lastname: Feldman
authors.forename: Eva
authors.initials: E
authors.lastname: Kaszper
authors.forename: Ibolya
authors.initials: I
authors.lastname: Varga
authors.forename: Edit
authors.initials: E
authors.lastname: Gláz
authors.forename: Károly
authors.initials: K
authors.lastname: Rácz
authors.forename: Miklós
authors.initials: M
authors.lastname: Tóth
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000150:complications* / Q000601:surgery / Q000628:therapy*; D000315:Adrenalectomy; D018246:Adrenocortical Adenoma / Q000601:surgery / Q000628:therapy*; D000324:Adrenocorticotropic Hormone / Q000097:blood; D050197:Atherosclerosis / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D003480:Cushing Syndrome / Q000097:blood / Q000209:etiology; D003920:Diabetes Mellitus / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone